 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 1 of 38  
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers 
in Older Adults: A Pilot  
 
[STUDY_ID_REMOVED]    
Unique Protocol ID: 2020P002042  
 
 
 
 
Steven E. Arnold MD  
Principal  Investigator  
Massachusetts General Hospital  
 
Denise Faustman MD, PhD  
Investigator  
Massachusetts General  
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Number: 2020P00 2042  
 
  
Version Number/Date : 7.0/28FEB2022  
 
The information contained herein is confidential and proprietary in nature and will not be disclosed to any third 
party without written approval of authorized designee. This document may be disclosed to the appropriate 
institutional review boards or to duly authorized representatives of the US Food and Drug Administration or national 
regulatory authority under t he condition that they maintain confidentiality.  
  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 2 of 38 STATEMENT OF COMPL IANCE  
 
This study will be conducted in compliance with the protocol, International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Good Clinical Practice (GCP), 
and the applicable regulatory requirements, United States Code of Federal Regulations (CFR) Title 45 CFR Part 46 
and Title 21 CFR Parts 50, 56, and 312.  
 
  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 3 of 38   
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 4 of 38 LIST OF ABBREVIATIONS  
AD   Alzheimer’s Disease  
ADC    Alzheimer’s Disease Center  
ADRD    Alzheimer’s Disease and Related Dementias  
BCG    Bacillus Calmette -Guérin  
CFR    Code of Federal Regulations  
CN   Normal cognition  
C-SSRS   Columbia Suicide Severity Rating Scale  
CRF    Case Report Form  
CSF    Cerebrospina l Fluid  
CMP    Comprehensive Metabolic Panel  
CRP    C-Reactive Protein  
eCRF    Electronic Case Report Form  
EDC    Electronic Data Capture  
ET   Early Termination  
ESR   Erythroid Sedimentation Rate  
FAQ    Functional Activities Questionnaire  
FDA    Food and Drug Administration      
GCP    Good Clinical Practice  
HIPAA    Health Insurance Portability and Accountability Act  
ICF    Informed Consent Form  
ICH    International Conference on Harmonisation  
IIR   Inflammation and Immune Response  
IRB    Internal Review Board  
MADRC   Massachusetts Alzheimer’s Disease Research Center  
MCI    Mild Cognitive Impairment  
MDU    Memory Disorders Unit  
MoCA    Montreal  Cognitive  Assessment  
NACC    National Alzheimer’s Coordinating Center  
NIA   National Institute on Aging  
NPIQ    Neuropsychiatric Inventory Questionnaire  
PCP   Primary Care Physician  
PI   Principal Instigator   
RBANS   Repeatable Battery for the Assessment of Neuropsychological Status   
SAE    Serious Adverse Event/Serious Adverse Experience  
SOB    Sum of Boxes  
SOP    Standard Operating Procedure  
TSH    Thyroid Stimulating Hormone  
Treg    Regulatory T -cells 
UDS    Uniform Data Sat  
US   United States  
WOCBP   Women of Child Bearing Potential  
  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 5 of 38 Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .....................  2 
SIGNATURE PAGE  ................................ ................................ ..................  ERROR! BOOKMARK NOT DEFINED.  
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ..............................  4 
1 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................ ................................ ........................  9 
1.1 Institutional Review Board (IRB)  ................................ ................................ ................................ ...........................  9 
1.2 Ethical Conduct of Study  ................................ ................................ ................................ ................................ .......  9 
1.3 Subject Information and Consent  ................................ ................................ ................................ ..........................  9 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ................................ ... 10 
3 STUDY DESIGN  ................................ ................................ ................................ ................................ .... 12 
3.1 Overall Study Design and Plan  ................................ ................................ ................................ ............................  12 
3.2 Study Objectives  ................................ ................................ ................................ ................................ .................  12 
3.3 Study Outcome Measures  ................................ ................................ ................................ ................................ ... 12 
3.3.1  CSF and Blood Biomarker Outcomes  ................................ ................................ ................................ .....................  12 
3.3.2  Cognitive Measure Outcomes  ................................ ................................ ................................ ................................  13 
3.3.3  Safety Measure Outcomes  ................................ ................................ ................................ ................................ ..... 13 
4 SUBJECT SELECTION  ................................ ................................ ................................ ............................  13 
4.1 Inclusion/exclusion Criteria  ................................ ................................ ................................ ................................  13 
4.1.1  Inclusion Criteria  ................................ ................................ ................................ ................................ ....................  13 
4.1.2  Exclusion Criteria  ................................ ................................ ................................ ................................ ...................  13 
4.2 Recruitment  ................................ ................................ ................................ ................................ .......................  15 
4.2.1  Recruitment of Subjects through Advertising  ................................ ................................ ................................ ........  15 
4.2.2  Recruitment of Subjects Identified through Private Medical Information  ................................ ............................  15 
4.2.3  Recruitment of Subjects from a mong the Investigator’s Own Patients  ...................  Error! Bookmark not defined.  
5 SUBJECT ENROLLMENT  ................................ ................................ ................................ .......................  16 
5.1 Informed Consent Process  ................................ ................................ ................................ ................................ .. 16 
5.2 Randomization  ................................ ................................ ................................ ................................ ...................  16 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 6 of 38 5.3 Remuneration  ................................ ................................ ................................ ................................ ....................  16 
5.4 Discontinuation  ................................ ................................ ................................ ................................ ..................  17 
5.4.1  Study Discontinuation  ................................ ................................ ................................ ................................ ............  17 
5.4.2  Discontinuation of Treatment  ................................ ................................ ................................ ................................  17 
5.4.3  Voluntary Withdrawals  ................................ ................................ ................................ ................................ ..........  17 
5.4.4  Lost to follow -up ................................ ................................ ................................ ................................ ....................  17 
5.5 Early Termination Visit (ET)  ................................ ................................ ................................ ................................ . 18 
5.6 Termination of Study  ................................ ................................ ................................ ................................ ..........  18 
6 STUDY PROCEDURES  ................................ ................................ ................................ ...........................  19 
6.1 Schedule of Events  ................................ ................................ ................................ ................................ .............  19 
6.2 Study Visits  ................................ ................................ ................................ ................................ .........................  20 
6.2.1  Screening  ................................ ................................ ................................ ................................ ...............................  20 
6.2.2  Baseline Visit/BCG Vaccine 1 (Day 1)  ................................ ................................ ................................ .....................  21 
6.2.3  BCG Vaccine 2 (Day 28 + 14 days)  ................................ ................................ ................................ ..........................  21 
6.2.4  Outcome Visit (Day 84 ± 5 days)  ................................ ................................ ................................ ............................  21 
6.2.5  Follow -up Phone Call (Day 98 ± 5 days)  ................................ ................................ ................................ .................  22 
6.2.6  Early Termination Visit  ................................ ................................ ................................ ................................ ...........  22 
6.2.7  Protocol Deviations  ................................ ................................ ................................ ................................ ................  22 
6.2.8  Missed Visits and Procedures  ................................ ................................ ................................ ................................  22 
6.3 Clinical Assessments  ................................ ................................ ................................ ................................ ...........  23 
6.3.1  Safety Measures ................................ ................................ ................................ ................................ .....................  23 
6.3.2  Physical and Neurological Examination  ................................ ................................ ................................ .................  24 
6.3.3  Phlebotomy for Target Engagement, Cytokine Levels and Biomarker Analysis  ................................ ....................  24 
6.3.4  Lumbar Puncture for Immune and Biomarker Analysis  ................................ ................................ .........................  24 
6.3.5  Vaccination Site Monitoring  ................................ ................................ ................................ ................................ .. 25 
6.4 Neurocognitive Assessments  ................................ ................................ ................................ ..............................  25 
6.4.1  Montreal Cognitive Assessment (MoCA)  ................................ ................................ ................................ ...............  25 
6.4.2  Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)  ................................ ...... 25 
6.5 Neuropsychiatric Assessments  ................................ ................................ ................................ ............................  25 
6.5.1  Neuropsychiatric Inventory Questionnaire (NPI -Q) ................................ ................................ ...............................  25 
6.5.2  Functional Activities Questionnaire (FAQ)  ................................ ................................ ................................ .............  25 
7 TREATMENT ADMINISTERED  ................................ ................................ ................................ ..............  26 
7.1 Study Drug  ................................ ................................ ................................ ................................ .........................  26 
7.2 Study Drug Packaging and Labeling  ................................ ................................ ................................ .....................  27 
7.3 Study Drug Storage  ................................ ................................ ................................ ................................ ................  27 
7.4 Study Drug Preparation  ................................ ................................ ................................ ................................ ...... 27 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 7 of 38 7.5 Dosage and Administration  ................................ ................................ ................................ ................................ . 27 
7.6 Study Drug Accountability  ................................ ................................ ................................ ................................ .. 27 
7.7 Study Drug Handling and Disposal  ................................ ................................ ................................ ......................  27 
7.8 Contraindications and Warnings  ................................ ................................ ................................ .........................  27 
7.8.1  Prohibited Medications  ................................ ................................ ................................ ................................ ..........  27 
7.8.2  Warnings  ................................ ................................ ................................ ................................ ................................  28 
8 BIOSTATISTICAL A NALYSIS  ................................ ................................ ................................ ..................  28 
8.1 Statistical methods  ................................ ................................ ................................ ................................ .............  28 
9 RISKS AND DISCOMFORTS  ................................ ................................ ................................ ..................  28 
9.1 BCG Vaccine Risks  ................................ ................................ ................................ ................................ ...............  28 
9.2 Lumbar puncture  ................................ ................................ ................................ ................................ ................  29 
9.3 Phlebotomy  ................................ ................................ ................................ ................................ ........................  29 
9.4 Neurocognitive testing  ................................ ................................ ................................ ................................ .......  29 
9.5 Neuropsychiatric and Functional Questionnaires  ................................ ................................ ................................  29 
9.6 Radiation  ................................ ................................ ................................ ................................ ............................  29 
9.7 Other Risks  ................................ ................................ ................................ ................................ .........................  30 
10 POTENTIAL BENEFITS  ................................ ................................ ................................ ......................  30 
11 MONITORING AND QUALITY ASSURANCE  ................................ ................................ .......................  30 
11.1 Independent Monitoring of Source Data  ................................ ................................ ................................ .............  30 
11.2 Safety Monitoring  ................................ ................................ ................................ ................................ ...............  30 
11.3 Adverse Event Reporting Guidelines  ................................ ................................ ................................ ...................  31 
11.3.1  Adverse Event  ................................ ................................ ................................ ................................ ........................  31 
11.3.2  Assessment and Recording of Adverse Events  ................................ ................................ ................................ ...... 33 
11.3.3  Assessment of Adverse Events  ................................ ................................ ................................ ..............................  33 
11.3.4  Relatedness of Adverse Event to Investigational Protocol  ................................ ................................ ....................  33 
11.3.5  Recording of Adverse Events  ................................ ................................ ................................ ................................ . 33 
11.3.6  Adverse Events and Serious Adverse Events - Reportable Events  ................................ ................................ .........  34 
12 DATA COLLECTION AND MANAGEMENT  ................................ ................................ .........................  34 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 8 of 38 12.1 Purpose of EDC  ................................ ................................ ................................ ................................ ...................  34 
12.2 Role of Data Management  ................................ ................................ ................................ ................................ .. 34 
12.3 Data Entry and Checks  ................................ ................................ ................................ ................................ ........  34 
12.4 Data Lock Process  ................................ ................................ ................................ ................................ ...............  34 
12.5 Data Handling and Record Keeping  ................................ ................................ ................................ .....................  35 
12.6 Confidentiality  ................................ ................................ ................................ ................................ ....................  35 
12.7 Retention of Records  ................................ ................................ ................................ ................................ ..........  35 
12.8 Publications  ................................ ................................ ................................ ................................ ........................  35 
13 REFERENCES  ................................ ................................ ................................ ................................ .... 36 
 
  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 9 of 38 1 ETHICS/PROTECTION OF HUMAN SUBJECTS  
 
1.1 Institutional Review Board (IRB)  
This study will be conducted in compliance with current Good Clinical Practices (GCP) and Title 21 Part 56 of 
the United States of America Code of Federal Regulations (CFR) relating to IRBs.  
 
1.2 Ethical Conduct of Study  
The study will be conducted in accordance with GCP defined by the International Conference on Harmonisation 
(ICH) and the ethical principles of the Declaration of Helsinki.  
 
1.3 Subject Information and Consent  
This study will be conducted in compliance with Title 21 Part 50 of the United States of America Code of Federal 
Regulations (CFR), Federal Regulations, and ICH Guidance Documents pertaining to inf ormed consent. At the 
first visit, prior to initiation of any study -related procedures, subjects will be informed about the nature and 
purpose of the study, participation/termination conditions, and risks and benefits. Subjects will be given adequate 
time to ask questions and become familiar with the study prior to providing consent to participate. Subjects will 
give their written consent to participate in the study and will be provided with a copy of the fully executed 
consent form for their records.  
  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 10 of 38 2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
 
2.1 Background Information  
2.1.1  Alzheimer’s Disease  and Mild Cognitive Impairment  
Alzheimer’s disease (AD) is the most prevalent form of dementia affecting more than 5,000,000 people  in the US 
and an estimated 20,000,000 people worldwide, according to the Alzheimer’s Association  1.  AD causes 
progressive neuronal degeneration, resulting in progressive memory loss, dementia and death. AD has no known 
cure or preventative as yet; however, treatments exist that can temporarily and modestly at best ameliorate 
dementi a symptoms.  
Mild cognitive impairment (MCI) is the term used when there is clinical concern about cognitive decline and 
evidence of impairment(s) in cognitive testing, more than expected for the patient's age and educational 
background, but not so severe that the person cannot manage their daily functioning without more than minimal 
assistance. MCI is frequently, though not always, a transitional, prodromal phase of dementia due to Alzheimer’s 
disease . "Dementia" is present when independent daily functioni ng is affected.  
AD is characterized by the presence of amyloid -β (Aβ) plaques, tau neurofibrillary tangles and loss of neurons 
and synapses in the cerebral cortex, particularly in association areas that subserve cognition. Aβ has been the 
target of many re cent clinical trials; however, these studies have failed to find that reducing amyloid meaningfully 
slows progression of dementia. It is increasingly evident that AD is a complex disorder with multiple metabolic, 
inflammatory, vascular and other pathophysi ological processes beyond amyloid and tau proteinopathies 
contributing to neurodegeneration. There is now increasing attention to intervening in these non -amyloid 
pathways to stem the tide of neurodegeneration in AD.  
2.1.2  Alzheimer’s Disease and the Immune Response  
Inflammation and immune responses (IIR) have major roles in the pathophysiology of Alzheimer's disease (AD). 
IIR encompasses many complex and highly regulated biological processes with which immune local tissue cells 
respond to tissue injury and maintain organ function and organismal homeostasis. AD's pathognomonic amyloid -β 
(Aβ) peptide itself is hypothesized to be a dysregulated ancient innate immune response to allo - or auto - stimuli in 
the brain.2 Aβ oligomers and aggregates in AD are thoug ht to elicit or exacerbate IIR,3 promoting vicious cycles 
of protein misfolding, endoplasmic reticulum stress, deranged metabolic signaling and mitochondrial function, 
oxidative/nitrosative stress, and cell death.  Th ere is tremendous interest and rapidly growing academic, biotech 
and pharma research on IIR therapeutic approaches in AD and AD -related disorders as similar vicious cycles have 
been proposed for a-synuclein pathologies in LBDs, 4,5 tau pathologies in FTD -tau and other tauopathies,6,7 and 
TDP -43 pathology in FTD -TDP and ALS.8,9  
Peripheral inflammatory markers may serve as biomarkers of AD disease state and distinguish healthy older 
adults from middle -aged adults, and healthy older adults from those with mild cognitive impairment (MCI) or 
Alzheimer’s Disease10. Inflammatory biomarkers may even predict those who will convert from MCI to AD over 
a two -year period  11-13. Innate immune function is affected by progression of AD; Monocytes of subjects with 
MCI or AD induce a greater NLRP3 and NLRP1 inflammasome response to extrinsically applied amyloid  beta 
than do healthy controls  14. The adaptive immune system is also involved in AD progression: T -cell reactivity to 
amyloid beta increases with age as well as progression of AD  10, and with worsening disease, cl onal populations 
of CD4+ and CD8+ T -cells can be found in the cerebrospinal fluid15,16. Regulatory T cells ( Tregs ) are of 
particularly significance to AD. While augmenting Tregs increases the number and function of microglia 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 11 of 38 associated with amyloid beta plaques, and improves cognitive functions12,17 -19, they are fewer in number over the 
course of disease20. 
There is tremendous and rapidly growing academic, biotech and pharma research on IIR therapeutic approaches in 
AD and AD -related disorders as similar vicious cycles have been proposed for -synuclein pathologies in LBDs, 
5,21 tau pathologies in FTD -tau and other tauopathies,22,23 and TDP -43 pathology in FTD -TDP and ALS.24,25  
2.1.3 BCG Rationale  
A potentially transformative IIR approach to AD prevention and disease modification that is safe, cheap and ready 
for testing now is Bacillus Calmette -Guérin  (BCG) vaccination. Live BCG vaccination has been the mainstay of 
prevention of tuberculosis for almost 100 years, administered in billions of people in more than 180 countries, 
from infants to the elderly. Its only significant contraindication is immunoco mpromise. "Off-target " benefits of 
BCG vaccination were recognized early in its 40% reduction of all -cause mortality in children and its prevention 
of non -mycobacterial infections,26,27 and BCG is now being explored in clinical trials as a prophylaxis against 
COVID -19.28 BCG has also demonstrated utility in treating non -infectious diseases. One major use is as a 
treatment for non -muscle -invasive bladder cancer, where high -dose intravesicular infusion is a treatment of 
choice,29 and there has been interest in BCG's beneficial associations and effects in other cancers,30-32 multiple 
sclerosis33-35 and type 136,37 and type 2 diabetes.38-41  
In the CNS, ‘sterile inflammation’ resulting fr om autoimmunity, misfolded proteins, or cell damage or death can 
result in a neurotoxic environment if not adequately kept in balance. T -regulatory cells, or Tregs can regulate 
immunologic balance by controlling microglial and antigen presenting cell (APC)  activation, inhibiting effector T 
(Teff) cells, and inducing astrocytic release of neurotrophins, thus effectively transforming a neurotoxic 
environment to a neurotrophic state. For example, two studies noted decreased neuronal cell death in a MPTP 
model of Parkinson’s Disease, finding that the magnitude of dopaminergic preservation correlated with the 
magnitude of Treg response to BCG treatment.42,43 BCG’s ability to induce and/or restore Treg immune balance is 
of great interest for treatment in AD,44,45 where precl inical models find that augmenting Tregs increases the 
number and function of microglia associated with plaques, and improves cognitive functions.18,46,47 In AD, Tregs 
may be overwhelmed due to their low numbers or dysfunction;48 BCG may increase Treg number and function to 
rebalance the neurotoxic state to one of neuroprotection.5  
Limited but provocative epidemiological analyses and in silico trial data support a benefit of BCG for AD. A 
large retrospective analysis found that older, non -demented adults treated with intrav esicular BCG for bladder 
cancer had a significant 4 -fold lower risk of subsequent AD over a median 8 -year follow -up period than those 
treated with other means.45   
BCG, a highly safe, live, attenuated vaccine used throughout the world to prevent tuberculosis  and confers many 
health -promoting non -specific effects, from preventing infectious disease to treating cancers. These effects rely on 
its induction of trained and heterologous immune responses in th e host. Such immune effects directly overlap and 
influence immune responses known to occur in CNS disease; non-human studies have found  benefit to BCG 
vaccination on models of Parkinson’s and Alzheimer’s diseases, including cognitive improvement.  These stu dies 
provide the impetus for our initiating clinical trials with BCG oriented towards primary prevention of AD in older 
adults or disease modification and secondary or tertiary prevention in adults whom AD pathological changes are 
already in motion. This p ilot study initiates this program , with focus on  the immune consequences of treatment  
and potential changes in AD -specific biomarkers and cognition after vaccination.  
 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 12 of 38 3 STUDY DESIGN  
 
3.1 Overall Study Design and Plan  
This single -site, open -label clinical trial will investigate the immune and neurobiological biomarker effects of 
BCG vaccination in healthy older adults and older adults with mild cognitive impairment (MCI) , and gather data 
on tolerability, safety and study feasibility. Twenty  participants  (approx. n=10 cognitively normal, n= 10 mild 
cognitive impairment ) will receive two intradermal BCG vaccinations  spaced  4 weeks apart and will be evaluated 
12 weeks after the initial immunization . Cerebrospinal fluid ( CSF) and blood will be  collected at Screening  (blood 
only) , Baseline, Week 4 (blood only) , and Week 12  for to assess safety , IIR and AD biomarker s. 
3.2 Study Objectives  
The primary objective of t his study is:  
1. To determine the most promising biomarkers of IIR  and neurodegeneration  in blood and CSF in terms of 
feasibility of measurement, technical specifications, and BCG  response of assays . 
The secondary  objectives of the study will be:  
1. To evaluate clinical neurobehavior changes from Baseline, including (M oCA, RBANS, NPI -Q and FAQ) 
following BCG vaccination . 
2. To assess the safety and tolerability of BCG vaccination in healthy older adults and older adults with 
MCI.  
3.3 Study Outcome Measures  
3.3.1 CSF and Blood Biomarker Outcomes  
CSF and blood will be collected at Baseline , Day 28 (blood only)  and Day 84 Visits  to examine  biochemical 
biomarkers of : 
1. Target engagement: BCG, purified protein derivative (PPD) and / or mycobacterium tuberculosis (heat - 
killed, mTB) – induced cytokine response in peripheral blood cells will be used to evaluate for BCG 
vaccine -induced immunity.   
2. Pharmacodynamic response: a ) Circulating cytokines and other related blood - and CSF -based IIR 
biomarkers relating to innate and adaptive immune responses; b) Epigenetic changes in peripheral blood 
cells and / or CSF - derived cell populations as indicators that BCG can lead to long t erm changes in 
peripheral and central nervous system immune cells.  
3. AD pathophysiology: Amyloid -β42/40, phospho -tau, total tau and / or neurofilament light protein 
biomarkers (ATN) and other exploratory AD -relevant synaptic and IIR biomarkers may be compare d 
within subjects over time and between subjects and groups.  
4. BCG effects on the interactions of IIR and amyloid: We will perform PBMC stimulation with Aβ42 and 
positive -control antigens (e.g. lipopolysaccharide) and measure the molecular response in the su pernatant 
at multiple timepoints after BCG /treatment. Aβ42 has immunostimulatory / inflammatory effects that 
increase with AD progression and may be modulated by an immune -provoking stimulus such as BCG.  
5. Additional related Alzheimer’s Disease and immune m easures in plasma, CSF, and their cell populations 
at the transcriptional, protein, or epigenetic levels.  
We have several robust platforms in the Arnold lab (which serves as the Biomarker Core of the Massachusetts 
Alzheimer's Disease Research Center) to co nduct these assays, including highly validated Euroimmun assays, 
Fujirebio Lumipulse assays, Meso Scale Discovery with plates run on a new Tecan EV0200 multi -functional robotic 
liquid handling platform, and Quanterix SR -X for ultrasensitive Simoa assays. W e have exhaustively validated 
many assays specifically for use in short -term clinical trials,49, and all  assays that we propose demonstrate good 
precision and biotemporal stability . Change in a composite score from Baseline  will be used as an outcome of 
response to BCG .  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 13 of 38  
3.3.2 Cognitive Measure Outcomes  
While we do not necessarily anticipate significant cognitive change within the study's duration, we will apply 
several robust clinical outcome measures to measure beneficial (or deleterious) effects of treatment , including the 
MoCA, RBANS, NPI -Q and FAQ.  
 
3.3.3 Safety Measure Outcomes  
Classic  metabolic, hematologic, and immune blood labs will be collected  at Screening, Day 28, and Day 84 Visits 
and monitored for change following BCG vaccination.  Four weeks after the first vaccination, we will assess the 
first vaccination site and evaluate for any signs of systemic infection prior to second BCG vaccination in the other  
arm. We will use the FDA Toxicity Grading Scale, as performed in vaccine trials , to denote changes from 
baseline . 
 
4 SUBJECT SELECTION  
Each Investigator must adhere to the protocol detailed in this document and agree that any changes to the pro tocol 
must be approved by Internal Review Board (IRB). Each investigator will be responsible for enrolling only those 
study subjects who have met protocol eligibility criteria.  
 
4.1 Inclusion/exclusion Criteria  
Investigators will use their best clinical judgme nt when selecting potential research subjects for this study and will 
not enroll any individuals who are frail or in questionable health, even if they meet all inclusion/exclusion criteria . 
 
4.1.1 Inclusion Criteria  
Study subjects meeting all of the following criteria will be allowed to enroll in the study:  
1. Individuals  between the ages of 55-80; 
2. MoCA ≥18; 
3. Normal cognition as defined by MoCA ≥ 26  or MCI as defined by the NIA-AA Workgroup  (2011)  and 
MoCA score between 18 and 25 (inclusive) ; 
4. Education level, English language skills and literacy indicates subject will be able to complete all 
assessments;  
5. Ability to provide informed consent ; 
6. Willing and able to complete all assessment and study procedures, including blood and lumbar punctures , 
and clinical assessments ; 
7. If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline ; 
8. Negative test results for HIV antibody and Tuberculosis (QuantiFERON) at screening ; 
9. No prior BCG exposure either through birth vaccinations (born in North American) or BCG bladder cancer 
treatment . 
10. Documentation of current flu season  vaccination dated at least 14 days prior to baseline visit.  
4.1.2 Exclusion Criteria  
Subjects meeting any of the following criteria during the screening evaluation will be excluded:  
1. History of chronic infectious disease, such as HIV or untreated or active hepatitis;  
2. History of tuberculosis, positive interferon -gamma release assay (IGRA, also known as the QuantiFERON -
TB test), including a test wit h a high reactivity to mycobacteria of non -tuberculosis variety;  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 14 of 38 3. Prior BCG vaccination, positive T -spot tuberculosis test or a T -spot test showing significant Mycobacteria 
exposure ; 
4. A positive  SARS -CoV -2 PCR  result  within 3 months  of screening , or known close contact with a confirmed 
COVID -19 positive person or symptoms highly suspicious for COVID -19 (per CDC guidelines)  within 1 
month of screening , including fever, cough, shortness of breath, chills, muscle pain, new loss of taste or 
smell, vo miting or diarrhea, and/or sore throat , based on clinician’s judgment ; 
5. History of treatment with metformin within the past one year;  
6. Previous participation (ever) in active immunization research for AD or passive immunotherapy or other 
disease -modifying treatme nts for AD within the past three months;  
7. Current treatment with immunosuppressants (calcineurin inhibitors, corticosteroids, or biological or 
cytotoxic immunosuppressants, or disease or condition likely to require high dose steroid or 
immunosuppressive therapy ); 
8. Other conditions or treatments associated with increased risk of infections  or treatment with 
immunosuppressive medications for any reason ; 
9. Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs ; 
10. Chronic use of ant ibiotics ; 
11. History of keloid formation ; 
12. Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example, 
HIV+ or taking immunosuppressive medications for any reason) , or in a job (e.g. healthcare) in which the 
subject wo rks with immunosuppressed populations ; 
13. Other/confounding neurological or psychiatric condition, unstable medical or psychiatric conditions, 
contraindications to BCG use and lab abnormalities or concurrent medication use posing risk for BCG or 
study procedures ; 
14. Laboratory abnormalities in B12, Folate, TSH, or other common laboratory parameters that may contribute 
to cognitive dysfunction;  
15. Laboratory abnormalities in CBC, electrolytes, LFTs, BUN,  Cr, total serum immunoglobulins, ESR, CRP, 
or urinalysis  posing risk to treatment with BCG  per clinician judgment ;  
16. Laboratory abnormalities in PT-INR, which would pose a risk to performing the lumbar puncture 
procedure ; 
17. Discontinuation of cholinesterase inhibitor or memantine within one month (28 day s) prior to baseline visit;  
18. Females who are pregnant, lactating or of child -bearing potential ; 
19. If male with female partner(s) of childbearing  potential, unwilling or unable to adhere to contraception 
requirements specified in the protocol ; 
20. Administration of live vaccine < 60 days prior to Baseline ; 
21. Increased intracranial pressure as determined on a fundoscopy/neurological exam ination  performed  within 
30 days of LP ; 
22. COVID -19 vaccination  < 14 days prior to baseline or any BCG  immunizations.  
 
4.1.2.1  Women of Childbearing Potential (WOCBP)  
For the purposes of this study, women of childbearing potential are defined as all women who are capable of 
becoming pregnant, unless they meet one of the following c riteria:  
1. 12-months post -menopausal.  
2. Post-hysterectomy.  
3. Surgically sterile.  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 15 of 38 If a female subject does not meet these criteria and is considered of childbearing potential, they will be excluded 
from the clinical trial.  
 
Male subjects with female partners of child -bearing potential must use at least 1 of the following contraceptive 
methods: hormonal contraceptives (oral, injectable, patch, intrauterine devices), a barrier method (such as 
condoms or diaphragm) used with a s permicide (a foam, cream, or gel that kills sperm), male sterilization, or total 
abstinence from heterosexual intercourse, when this is the preferred and usual lifestyle of the subject. Abstinence 
is defined as refraining from heterosexual intercourse duri ng the entire period of risk associated with the study. 
Note that periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method are not acceptable methods of con traception.  
 
4.2 Recruitment   
Up to  twenty -six subjects will be screened  and enrolled in the study , and after screening we expect twenty  subject s 
to complete the study.   
 
4.2.1 Recruitment of Subjects through Advertising  
Advertisement flyers will be posted on bulletin boards around  MGB campuses  to advertise for the study  as well as 
an advertisement on Partners Rally for Research . A phone number will be provided that will ring directly to the 
research coordinator, and voice messages can be left for the coordinat or on a password -protected voice mailbox.  
The study coordinator will contact the subject and explain study in further detail and if the subject is interested, 
potentially complete a telephone prescreening.  A listing of the study will also be posted on the MGH ACTRU 
website.      
 
4.2.2 Recruitment of Subjects from among MGB Providers   
Subjects will be recruited from the outpatient clinical practices of the principal investigator (Dr. Steven Arnold). If 
the potential subject is the investigator’s patient, another m ember of the study or clinic staff will introduce the study 
to the patient and determine if they are interested in learning more about the study. An NP investigator will be made 
available to explain the study to the subject at their request. If the potenti al subject is not the investigator’s patient, 
the investigators will not directly approach the patient regarding possible participation in the study.  
 
Other providers across MGB will also be made aware of the study (including key eligibility criteria) via email and 
provided with a link to the Rally ad. These providers (not participating directly in the study) may discuss the study 
directly with their patients, if they choose to do so. If the prospective participant is interested, their provide r will 
give them a copy of the consent form (unstamped) for review as well as a link to the Rally ad, which contains the 
research coordinator’s contact information.  
 
4.2.2.1  Recruitment of Subjects from the Massachusetts Alzheimer’s Disease Research Center  
Subjects will also be recruited from an observational study that follows a longitudinal research cohort (LC) of 
approximately 400 active research participants in the Massachusetts Alzheimer's Disease Research Center 
(MADRC) recruited from the MGH’s Memory Disorders Unit clinic and other diverse sources. LC subjects are 
followed -up on an approximately annual basis, either in -person at the MGH or by means of a telephone follow -up 
‘visit’. Study staff will only contact subjects that have indicated to the MADRC  that they are interested in hearing 
about/participating in other studies.  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 16 of 38 5 SUBJECT ENROLLMENT  
 
5.1 Informed Consent Process   
This study will be conducted in compliance with Title 21 Part 50 of the United States of America Code of Federal 
Regulations (CFR), Fe deral Regulations, and ICH Guidance Documents pertaining to informed consent.  
 
Potential subjects will be given general information about the research (e.g., through informational sheets, letters, 
or discussion with their treating physicians). If they are  interested in learning more about the study, they will then 
contact the research coordinator. The research coordinator will obtain verbal consent in accordance with Partner’s 
Prescreening Guidelines prior to performing a telephone prescreening interview.  If the subject meets pre -screening 
criteria and wishes to continue the screening process, an in -person screening visit will be scheduled.  
 
At the screening  visit, an investigator will meet with the potential subject to review and discuss the details of the 
study using the informed consent document as a guide. This discussion will include all the required elements of 
informed consent, including the purpose of the resear ch, the procedures to be followed, the risks and discomforts, 
as well as potential benefits associated with participation, and alternative procedures to study participation. Their 
questions will be answered to their satisfaction.  The subject will be provi ded with adequate time to reflect on the 
potential benefits and risks and possible discomforts of participation, and to make an informed decision. A licensed 
Nurse Practitioner Investigator or Physician Investigator will then obtain written informed consen t from each 
participant prior to the initiation of any study procedures. All potential subjects  will be given the opportunity to 
speak with the Physician Investigator should a licensed Nurse Practitioner be involved in obtaining informed 
consent. While som e subjects will have MCI  or subjective memory loss , they must be deemed capable of providing 
informed consent by the Nurse Practitioner or Physician Investigators. Subjects who are not capable of providing 
informed consent will be excluded from this study.   
 
 
5.2 Randomization  
This is an open -label trial and all participants will receive active treatment.  
 
5.3 Remuneration  
All subjects will receive:  
• Parking fees paid for all in -person visits  
• Lunch voucher provided for subject at each study visit  that exceed s two hours , which can be used 
at the cafeteria at MGH CNY 149  
• If appropriate, travel expenses will be reimbursed, including mileage at 58 cents per mile, up to 
$150 per visit   
• Honoraria: Up to $ 315 if subject completes the study:   
o $15 for the screening visit  
o $25 for  the Day 1, Day 28, and Day 84 visits  ($75 total)  
o $100 for each lumbar puncture (x 2)  
o $25 upon study completion  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 17 of 38 • If for any reason the subject stops the study, they will be compensated for only the visits that they 
have completed  
Payment will be made in the form of a check mailed to the subject's home address. They should receive the check 
within 2 -3 weeks from the date of the study visit. Their social security number (SSN) will be requi red in order to 
process the payments.  
 
5.4 Discontinuation  
5.4.1 Study Discontinuation  
A study subject will be discontinued from participation in the study if:  
1. Any clinical adverse event (AE), concurrent illness, or other medical condition or situation occurs such  that 
continued participation in the study would not be in the best interest of the subject.  
2. The subject meets any exclusion criteria (either newly developed or not previously recognized)  and/or fails 
to continue to meet inclusion criteria  which the  study physician deems to be a risk to continued participation.  
5.4.2 Discontinuation of Treatment  
Individual subjects will be allowed to continue in the study, but a dministration of the second immunization  will 
be withheld if , after the first injection , any of the following criteria are met:  
1. Any of the following serious adverse events attributable to BCG:  
• Life-threatening adverse event  
• Permanent or severe disability  
• Important BCG -specific medical events that do not result in death, are not life -threatening, and/or 
do not require hospitalization will be considered as serious if, based on appropriate medical 
judgment, they jeopardize the participant and would require m edical or surgical intervention to 
prevent a serious adverse event.  
2. Presentations of symptoms of disseminated BCG infection including persistent fevers, night sweats, 
weight loss. These symptoms usually do not occur within the timeline of the current study  (usually 4 
months to 2 years after vaccination), however should such symptoms occur prior to the second 
immunization, the treatment would be stopped.  
3. The occurrence of any serious local skin reactions (≥ grade 3 ulceration, abscess formation, skin necrosi s 
at the site of vaccination, or the development of suppurative lymphadenitis) as characterized by the 
standard FDA Toxicity grading scale ( https://www.fda.gov/regulatory -information/search -fda-guidance -
documents/toxicity -grading -scale -healthy -adult -and-adolescent -volunteers -enrolled -preventive -vaccine -
clinical ).  
5.4.3 Voluntary Withdrawals  
A subject may choose to discontinue participa tion in the study at any time. An E arly Termination Visit will occur  
when a subject withdraws consent, i.e. withdrawing his or her participation in future study procedures . 
 
5.4.4 Lost to follow -up 
The following actions must be taken in relation to a subject who fails to attend the clinic for a required study visit:  
•  The site must attempt to contact the subject and re -schedule the missed visit as soon as possible.  
•  The site must counsel the su bject on the importance of maintaining the assigned visit schedule 
and ascertain whether or not the subject wishes to and/or should continue in the study.  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 18 of 38 •  In cases where the subject is deemed ‘lost to follow up’, the Investigator or designee must make 
every effort to regain contact with the subject (where possible, 3 telephone calls and if necessary 
a certified letter to the subject’s last known mailing address or local equivalent methods). These 
contact attempts should be documented in the subject’s study record.  
•  Should the subject continue to be unreachable, only then will he/she be considered to have 
withdrawn from the study with a primary reason of “Lost to Follow -up”. 
 
5.5 Early Termination Visit  (ET)  
Subjects who decide to withdraw from the study at any point after receiving the initial BCG immunization will be 
invited to come in for an Early Termination Visit. 
5.6 Termination of Study  
This study may be prematurely terminated if, in the opinion of the inv estigator, there is sufficient reasonable 
cause.  
 
Circumstances that may warrant termination include, but are not limited to:  
1. Determination of unexpected, significant, or unacceptable risk to subjects ; 
2. Unsatisfactory enrollment ; 
3. Insufficient adherence to  protocol requirements ; 
4. Data that are not sufficiently complete and/or evaluable ;  
5. If any grade 3 “severe” or higher adverse event occurs in three or more participants, or if participants 
have severe systemic reactions to the antigenicity of the vaccinatio n with respiratory problems, the study 
protocol will be paused for review. The FDA, and all other relevant oversight bodies will be notified in a 
timely fashion if a batch of BCG is problematic. If during the study three or more subjects, representing 
greater than 25% of enrolled subjects, develop a systemic BCG infection in the absence of an underlying 
immunocompromised state, the study will be stopped for a study of this side effect.  
 
If the study is prematurely terminated or suspended, the investigators will promptly inform the institution and 
regulatory authorities of the termination or suspension and the reason(s) for the termination or suspension. The 
IRB will also be informed promptly and provided the reason(s) for the termination or suspension by the 
investigator, as specified by applicable regulatory  requirement(s).
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 19 of 38 6 STUDY PROCEDURES  
  
6.1 Schedule of Events  
Activity  Phone 
Screen  Screen ing 
Visit  Baseline 
Visit/ 
BCG 
Vaccine 1  BCG     
Vaccine 
2 Outcome    
Visit / Early 
Term ination  Check -In 
Phone  
    <-28days Day 1  Day 28  
+14 days Day 84  
±5 days  Day 98 
±5 days 
Informed Consent    x         
Inclusion/Exclusion Review  x x         
Demographics  x x         
Create IBCID   x          
Medical History  x x         
Concomitant Medication Review  x x x x x x 
Family History    x         
Vital Signs, Height, Weight1   x x x x   
Physical & Neurological Exam    x         
Screening Lab Tests for  Eligibility2   x         
BCG Vaccination      x x     
Vaccination Site Monitoring     x x x   
Fundoscopy      x  
Safety Lab Tests3       x x   
Blood Draw for Biomarkers4     x x x   
COVID -19 Testing5  x     
PT/INR    x    x   
Fasting Lumbar Puncture  for 
Biomarkers4   x  x  
MoCA and  FAQ   x   x  
Cognitive/Behavioral  Assessment6    x   x   
Adverse Event Review    x x x x x 
 
[1] Height and weight will be measured and recorded at the Screening visit only.  
[2] Eligibility  lab tests include  CBC  with diff , CMP, TSH, Folate, B12, HIV antibod ies, serum immunoglobulins, ESR, CRP, 
QuantiFERON -TB Gold Test, urinalysis  
[3] Safety lab te sts includ e CBC  with diff , CMP , CRP and ESR . 
[4] Blood biomarkers will include PBMCs for PPD  and amyloid -beta stimulation assay / flow cytometry, and serum for IIR 
and AD biomarkers . CSF biomarkers  will be used for cytology, IIR and AD biomarkers  tubes for monocyte levels of innate 
immunity . 
[5] COVID -19 Testing includes SARS -CoV -2 PCR (nasal swab)  
[6] Cognitive assessments will include  RBANS, NPI -Q 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 20 of 38 6.2 Study Visits  
6.2.1 Screening  
6.2.1.1  Telephone  Pre-Screening  
Subjects will be screened over the phone by study staff to determine eligibility and to ensure that the subject is 
safe to undergo all study assessments. These procedures include:  
• Obtain verbal pre -screening informed consent from subject  
• Assess inclusion  and exclusion criteria  
• Collect brief demographics  
• Obtain neurocognitive disease diagnosis history, family history, and medical history , including COVID -
19 diagnosis and previous exposure risk  
• Review and document concomitant medications and therapies  
During this call, study procedures will be discussed in detail and the subject will be given an opportunity to ask 
questions about the study. All other study procedures will take place after signing an IRB -approved consent form 
in person.  
 
6.2.1.2  Screen ing Visit  
All subjects who pass a telephone pre -screening will be invited to MGH  CNY  for a study visit.  If necessary, some 
of the following procedures may be performed virtually to minimize the length of the office visit.   This screening 
visit will take a pproximately two hours.  The following procedures will be performed at the visit:  
• Obtain written informed consent from subject  
• Review inclusion and exclusion criteria, medical history  including COVID -19 history  and demographics, 
concomitant medications and  therapies  
• Vital signs, height, and weight  
• Perform a physical , including inspection for BCG scar on either deltoid  
• Perform a neurological examination  
• Perform nasal swab testing of SARS -CoV -2 PCR  
• Urinalysis  
• Phlebotomy for screening tests 
o CBC with differential  
o Comprehensive metabolic panel (CMP)  
o Thyroid stimulating hormone (TSH)  
o B12  
o Folate  
o HIV antibod ies 
o Tuberculosis (QuantiFERON -TB Gold Test ) 
o C-Reactive Protein (CRP)  
o Eryth rocyte sedimentation rate (ESR)  
o Serum immunoglobins  (IgA, IgG, IgM)  
o PT/INR  
• MoCA (version 8.1)  
• FAQ  
• Assess and document adverse  events (AEs) after subject signs ICF   
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 21 of 38  
6.2.1.3  Screen Failures  
Any subject who signs consent will be considered enrolled in the study. If a subject fails screening, at a minimum, 
the following information should be captured and entered into the Electronic Data System (EDC).  
• Inclusion/Exclusion Criteria  
• Demographics  
• Reason for screen failure  
6.2.1.4  Re-screening  
One re -screen is allowed ≥30 days after the initial screening. All screening procedures will be repeated at the re -
screen visit.  
 
6.2.2 Baseline  Visit/BCG Vaccine 1  (Day 1)   
All subjects who pass screening will return to MGH  CNY  for the Baseline visit.  At this visit, all baseline clinical 
measures will be collec ted, and the first BCG vaccine injection will be administered. The Baseline visit will occur 
within 2 8 days of the Screening visit. If necessary, baseline measures may be collected up to 3 days before the 
Day 1 vaccination visit . The visit will take approximately three  hours and will include:  
• Vital signs  
• Assess any changes to medical history, concomitant medications and/or adverse events  
• Neurobehavioral assessments  
o RBANS  
o NPI-Q 
• Phlebotomy for biomarker  research  
• Fasting lumbar punctu re for biomarker research  
• First BCG vaccine administ ration  followed by 30 min utes of  monitoring  
 
6.2.3 BCG Vaccine 2 ( Day 28 + 14 days )   
Subjects will be asked to return to MGH  CNY  for a second BCG vaccination  visit 28 (+ 14) days after the first 
vaccination . This visit will take approximately one hour and will include:  
• Vital signs  
• Assess any changes to medical history, concomitant medications and/or adverse events  
• Phlebotomy for safety labs  
• Phlebotomy for biomarker research  
• Vaccine site monitoring  
• Second BCG vaccine administered followed by 30 minutes of monitoring  
 
6.2.4 Outcome  Visit  (Day 84 ± 5 days ) 
Subjects will be asked to return to MGH CNY for the final in -person visit at Day 84  (± 5) days to assess study 
outcomes . This visit will take approximately three hours and will include:  
• Vital signs  
• Assess any changes to medical history, concomitant medications and/or adverse events  
• Vaccine site monitoring  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 22 of 38 • Neurobehavioral assessments  
o FAQ  
o MoCA  (versi on 8.1) 
o RBANS  
o NPI-Q 
• Phlebotomy for safety labs  
• Phlebotomy for biomarker research  
• Point of care PT/INR testing for lumbar puncture safety  
• Focused Exam: Fundoscopy  
• Fasting lumbar pun cture for biomarker research  
 
6.2.5 Follow -up Phone Call ( Day 98  ± 5 days ) 
All subjects who complete the Outcome  visit will be called on Day 98 (± 5) days by the study coordinator or 
clinician to review  changes to concomitant medications and/or adverse events.  
 
6.2.6 Early Termination  Visit   
If the subject withdraws from the study before completion of all study visits , they may be invited to return to 
MGH CNY for a final visit. This visit will take approximately 2 hours and will include the following measures:  
• Vital signs  
• Assess any changes t o medical history, concomitant medications and/or adverse events  
• Neurobehavioral assessments – RBANS, NPI -Q, FAQ, MoCA  
• Phlebotomy for biomarker  research  
• Phlebotomy for safety lab testing  
• PT/INR (if opting for lumbar puncture ) 
• Optional fasting lumbar puncture  
The option to decline any of the early termination  procedures or the entire visit will be given to all participants 
withdrawing from the study.  
6.2.7 Protocol Deviations  
A protocol deviation is any noncompliance with the current clinical trial protocol. The noncompliance may be on 
the part of the subject, the PI or Co -Is, or the study staff. As a result of deviations, corrective actions will be 
developed by the PI or Co -Is and implemented promptly. All deviations from the protocol must be addressed in the 
subject’s documents. Protocol deviations will be sent to the IRB per their guidelines and entered in the Protocol 
Deviations Log in the EDC System . 
6.2.8 Missed Visits and Procedures  
Missed visits and any procedures not performed (not attempted) for reasons other than illness, injury , or progressive 
disability  (i.e.: a subject is physically unable  to perform them) will be reported as protocol deviations.  
Procedures or visit s not performed due to illness, injury , or disability, including procedures t hat were attempted but 
failed ( i.e.: blood samples unable to be drawn after multiple attempts or weight unable to be obtained due to subject 
immobility)  will not be reported as pr otocol deviations.  
 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 23 of 38 6.3 Clinical Assessments  
Assessments will be performed at designated time -points throughout the study for clinical evaluation. In addition 
to the assessments evaluated below, subjects will provide information on their demographics, past me dical and AD 
history, family history, and medication usage.   
 
Subject interviews  and the neurocognitive and neuropsychiatric assessments detailed below  may be conducted 
virtually using Zoom videoconferencing platform depending on institutional guidance rel ating to the COVID -19 
pandemic and subject consent . Any visit components conducted virtually will be documented as such  and efforts 
will be made to collect all intrasubject clinical assessments in the same format (virtually or in person) . 
 
6.3.1 Safety M easures  
6.3.1.1  Vital Signs, Height, Weight  
Vital signs, including systolic and diastolic blood pressure, pulse rate (radial artery)/mi nute, respiratory rate/minute, 
and temperature will be assessed at  the Screening, Baseline , Day 28 , and Day 84  visits.  Verbal weight may be 
documented for those subjects utilizing a wheelchair. Height and weight will be measured and recorded at the 
Screeni ng visit only.  
 
6.3.1.2  Clinical Laboratory Assessments  
Study participants will be asked to provide approximately 25 mL of blood for eligibility and safety lab analysis at 
the Screening visit , 11 mL for safety lab analysis at Day 28 , and 12 mL for safety lab analysis at Day 84 , for a total 
of 48 ml (3.3 tablespoons ) throughout the study. The participant will have his or her whole blood collected by either 
a nurse or phlebotomist from a peripheral vein. Blood will be handled, processed, an d analyzed in accordance with 
regulations set forth by  the American Society for Clinical Pathology and the College of American  Pathologists.  
Safety Laboratory Tests  
Lab test  Source  Volume required 
[mL] (total)  Completed  at 
following visits  
Coagulation Testing (PT/INR)  Finger prick or 
intravenously from 
peripheral vein  1 (2) Screening , 
Day 84  
Complete Blood Count with Differential  Testing  
Intravenously from 
peripheral vein  3 (9)  Screening, Day 28 , 
Day 84  
Complete Metabolic Panel  Testing  5 (15)  Screening, Day 28 , 
Day 84  
C-Reactive Protein Testing (CRP)  1 (3)  Screening, Day 28 , 
Day 84  
Erythrocyte Sedimentation Rate (ESR)  2 (6)  Screening, Day 28 , 
Day 84  
HIV Antibody Testing  6 (6)  Screening  
QuantiFERON -TB Gold Test  4 (4)  Screening  
Serum Folate / B12 Testing  1 (1)  Screening  
Serum Immunoglobins  1 (1)  Screening  
Serum Thyroid Stimulating Hormone  Testing  1 (1)  Screening  
Urinalysis  Urine cup  10 (urine)  Screening  
SARS -CoV -2 PCR  Nasal swab  n/a Screening  
 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 24 of 38 All subjects will have safety laboratory tests at the designated visits outlined in the protocol. These samples will be 
analyzed at a central laboratory.  The SI may order additional testing, if thought to be necessary, to further assess an 
adverse event (A E), or if there is any suspicion that a subject may be pregnant, throughout the course of the study.  
Tests for Complete Blood Count ( CBC ) and Prothrombin Time and International Normalized Ratio ( PT/INR ) which 
are required prior to performing a lumbar punct ure may be performed using CLIA waived point of care testing using 
the Sysmex XW -100 CBC analyzer and the Roche CoaguChek XS Plus PT/INR analyzer.  
6.3.2 Physical and Neurological Examination  
A physical and neurological examination will be performed at the Screen ing visit. The following systems will be 
examined: general appearance, head, eyes, ears, nose, throat, neck, chest, heart, abdomen, extremities, edema, 
peripheral vascular, skin and appendages, musculoskeletal, central nervous system and back.  
A focused fundoscopy examination will be repeated  at the outcome visit for assessment of increased intracranial 
pressure.  
6.3.3 Phlebotomy for Target Engagement , Cytokine Levels  and Biomarker Analysis  
Subjects will provide additional blood samples for biomarker analysis at Day 1 , Day 28 , and Day 84  visits . Target 
engagement will determine whether the subject ’s immune system  has responded  to BCG.  In general, whole blood 
will be either collected and utili zed for biochemical / metabolic assays, or spun in EDTA -containing tubes with 
plasma being frozen for cytokine analysis of IIR and / or AD biomarkers. Remaining plasma may be used for other 
biochemical analyses. Peripheral blood mononuclear cells (PBMCs) w ill be isolated from the cell pellets, some of 
which will be frozen for later culturing and cell -stimulation studies. Other PBMCs will be further isolated into 
subpopulations of cells and frozen for epigenetic analyses (e.g. ATACseq) and possibly subject t o other 
immunostaining or quantitative biochemical assays.   
 
60 ml (3.9 tablespoons)  of blood will be collected for these analyses  at the  Day 1, Day 28 , and Day 84  visits for a 
total of  180 ml (12.2 tablespoons ) over the course of the study. Blood processing will occur on site at MGH.  Blood 
samples will be de -identified, codified, and  stored on -site at the Arnold Lab biorepository. Blood samples will be 
stored for research until they are used, damaged, or otherwise unfit for analysis.  
 
6.3.4 Lumbar Punctu re for Immune and Biomarker Analysis  
Lumbar punctures (LP) will occur at Baseline  and Day 84  visits . Lumbar punctures will be performed after a 
minimum of an 8 hour fast. The subject will be positioned seated or lying on his/her side on the examination tab le. 
Standard protocols will be used employing palpation to identify the L3 -4, L4 -5 or L5 -S1 vertebral interspaces, 
sterile conditions, local lidocaine anesthesia, and use of standard of care spinal needles.  Clinical judgement will be 
used to determine the optimal spinal needle type/ size for each participant.  Lumbar punctures will be performed by 
qualified, experienced practitioners.  Approximately 25 mL of CSF at each designated visit will be collected. A 
small portion of this volume will be used for analysis of cell count with differential, total protein, and glucose. The 
remainder will be spun and cells isolated from supernatant. Supernatant will be frozen for later immunoassays. Cells 
will be frozen for later biochemical analyses.  Subjects will also  complete a brief REDCap  survey after the LP in  
which they will answer questions about the tolerability of the procedure. After the LP is complete, subjects will be 
given time to eat breakfast or have a snack before continuing with the visit.  
 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 25 of 38 If a subjec t has difficult back anatomy or is particularly overweight, and the physician or nurse practitioner does 
not feel comfortable performing the LP because they are not able to locate the proper lumbar landmarks, the subject 
will be scheduled to undergo the LP  under fluoroscopy at MGH Interventional Radiology. Fluoroscopy time will 
vary person to person. The average radiation dose is 0. 18 millisieverts (mSv), or the equivalent of 21 days of natural 
background radiation.  
CSF samples will be de-identified, codified, and stored on -site at the Arnold Lab biorepository. CSF samples will 
be stored for research until they are used, damaged, or otherwise unfit for analysis.  
 
6.3.5 Vaccination Site Monitoring  
Prior to the first vaccination, both deltoids w ill be inspected to confirm there is no evidence of previous BCG 
vaccination and no obvious  symptoms that would contraindicate vaccine injection. At the Day 28 visit , prior to the 
second injection, the vaccination site will be inspected for any signs of  local infection. At the  Day 84 visit  and if 
indicated by  subject -reported AEs , the site of vaccination on the arm will be examine d and any visible reactivity 
will be recorded.  
6.4 Neurocognitive  Assessments  
6.4.1 Montreal Cognitive Assessment (MoCA)  
The Montreal C ognitive Assessment (MoCA) is a commonly utilized questionnaire in clinical trials and research 
settings to measure levels of cognitive impairment.54 The MoCA measures five areas of cognitive function: 
orientation, visuospatial, attention and ca lculation, recall, and language. The MoCA (version 8.1) will take 
approximately 1 5 minutes to complete. The MoCA will be administered at the Screening visit to determine subject 
eligibility (MoCA >18) and at the Outcome  visit.   
 
6.4.2 Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)   
The RBANS55 is a commonly used 25 -minute, standardized neurocognitive batter y. The RBANS measures five 
neurocognitive domains, with twelve subtests measuring cognitive decline or improvement with immediate memory 
(List Learning and Story Memory), visuospatial/constructional (Figure Copy and Line Orientation), language 
(Picture naming and Semantic Fluency), attention (Digit Span and Coding), and delayed memory (List Recall, List 
Recognition, Story Memory, and Figure Recall).  The RBANS has been shown to be effective at both detecting and 
characterizing forms of dementia. The Delayed Memory domain has been sho wn to be particularly sensitive to 
discriminating mild cognitive impairment (MCI) due to Alzheimer's disease from controls, and also is predictive of 
cerebral amyloid burden. The RBANS will be administered at the Baseline  and Outcome  visits.  
 
6.5 Neuropsychiatric Assessments  
6.5.1 Neuropsychiatric Inventory Questionnaire (NPI -Q) 
The NPI -Q57 will rate symptoms in 12 sub -domains of behavioral functioning including: hallucinations, delusions, 
agitation, dysphoria, anxiety, euphori a, apathy, disinhibition, irritability, aberrant motor activity, eating 
abnormalities, and night -time behavioral alternations.  The NPI -Q will be done at the Baseline and Outcome  visits.  
 
6.5.2 Functional Activities Questionnaire (FAQ)  
The FAQ12,53 is a brief rating scale used to determine a subjects’ le vel of functional independence when performing 
a range of instrumental activities of daily living (IADLs), with repeat assessments useful for monitoring 
performance in these areas over time. The FAQ total score (ranging from 0 -30) reflects the sum of ordin al ratings 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 26 of 38 (0 = fully independent, 1 = has difficulty but does by self, 2 = requires assistance, and 3 = dependent) across ten 
items assessing a variety of functional activities (i.e., preparing a balanced meal, financial management skills, and 
shopping), with higher scores indicating increasing levels of dependence. For activities not normally undertaken by 
a person, a score of 1 is assigned if the subject would be unable to complete the task if required, or a score of 0 is 
assigned if the subject believes  they could successfully carry out the task if needed. Overall, the FAQ is a sensitive 
marker of functional impairment among individuals with varying dementia severity and has been shown to 
differentiate mild cognitive impairment from early dementia due to  Alzheimer’s Disease with 80% sensitivity and 
87% specificity. The FAQ demonstrates high reliability (exceeding 0.90), takes about 5 minutes to complete, and 
requires limited rater training to administer.  The FAQ will be done at the Screening  and Outcome  visits.  
 
7 TREATMENT ADMINISTERED  
 
Summary of Investigational Products  
 Investigational Products  
Product Name:  Tokyo BCG (JBL, Tokyo, Japan)  Diluent (0.9% sodium chloride for 
injection)  
Dosage Form:  For intradermal injection  For intradermal injection  
Unit Dose  1.8-3.9 x 106 colony forming units 
(CFU)/injection of 0.1ml  0.1 mL  
Route of Administration  Intradermal injection  Intradermal injection  
Physical Description  sterile, freeze -dried; packaged with a sterile, 
normal saline dil uent  BCG diluent  
Manufacturer  Japan BCG Laboratory (JBL)  Japan BCG Laboratory (JBL)  
 
7.1 Study Drug  
Japan BCG is an approved drug in Japan, and has been sanctioned by UNICEF and WHO as a standard vaccine 
for the prevention of tuberculosis. BCG has been administered for this purpose for over 100 years on a global 
basis, with typical distributions of over 50,000,000 doses to newborns per year. The vaccine has also been 
approved and utilized for treatment of bladder cancer for the past 30 years.  
Dr. Faustma n manufactures the only GMP -quality BCG in the world through contract agreements with the 
Japanese government. Th is protocol will be reviewed by th e Japanese government  ethics committee  prior to 
commencement of study activities.  Drug -related contracting wi ll occur through Dr. Faustman who maintains the 
Master Drug File, coordinates various IND filing around this vaccine and will interface with regulatory affairs 
management.  
The study drugs (BCG vaccine and diluent) are manufactured by Japan BCG ( Tokyo , Japan) and will be managed 
and stored by the  study pharmacist  in the Faustman lab  according to the directions provided by the manufacturer 
in the approved product labeling.  The same study pharmacist and study drug  have been used for the past 6 years 
in Dr. Faustman’s  protocol #2013P002633 .  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 27 of 38 Japan BCG is a freeze -dried preparation made from the Tokyo 172 strain of Mycobacterium bovis  Bacillus 
Calmette and Guérin (BCG).  Japan BCG is an attenuated BCG product derived from the original attenuated BCG 
generat ed by Albert Calmette and Camille Guerin at the Pasteur Institute.  
7.2 Study Drug Packaging and Labeling  
The Japan BCG drug product is a sterile, freeze -dried preparation of BCG. The drug product is packaged with a 
sterile, normal saline diluent.  
7.3 Study Dru g Storage  
This drug is stored with 4oC refrigeration.  
7.4 Study Drug Preparation  
The BCG vaccine is supplied as a 10 -dose ampoule. For reconstitution, 1.0 ml of sterile saline is added to the 10 -
dose ampoule. Each 0.1ml dose is drawn by syringe from the ampoule following reconstitution and administered 
intradermally.  Once reconstituted, the pharmacy provides the study clinic with the pre -filled syringe in a covered 
surgical tray to prevent light exposure. If the prepared syringe cannot be immediately admi nistered, it will be 
temporarily stored at  4oC until administration (< 1 hour from reconstitution) .  
Each  ampoule may be used for a maximum of two study participants  in this pilot study of 12 participants . In this 
case, the ampoule  will be reconstituted, a nd the syringes drawn at the same time. As above, the prepared syringes 
will be covered and stored at 4oC until administration within  1 hour of reconstitution. The remaining unused 
volume in the ampoule will not be used for additional patients in this pilot trial .  
7.5 Dosage and Administration  
All subjects will be consented by a study clinician  before any of the following procedures are done. The skin site 
(deltoid region, alternating between first and second dose) is first cleansed with an alcohol or acetone sponge and 
allowed to dry thoroughly.  Next, 1.8-3.9 x 106 colony forming units (CFU) , reconstituted  by the study pharmacist  
in 0.9% saline diluent  within 1 hour , will be administered intradermally via a 15mm, 26-gauge  needle.   
Dose selection is based on published data illustrating that two doses of  BCG in autoimmune type 1 diabetes 
confer the immune regulatory/inflammation modulation properties that are of interest in the present study. 
Specifically, administration of two doses in type 1 diabetes is associated with short term changes in biomarkers 
with 22 weeks of observations. 36 Moreover, two doses of BCG resulted in a clinical correction of HbA1c in type 
1 diabetes with stable correction of disease process for 8 years.  37 
7.6 Stud y Drug Accountability  
Vaccine accountability will be maintained by the  study pharmacist.  
7.7 Study Drug Handling and Disposal  
Vaccine handling and disposal will be managed by the study pharmacist.  
7.8 Contraindications and Warnings  
7.8.1 Prohibited Medications  
Treatment with the following medications during the study is prohibited:  
• metformin  
• aspirin > 160 mg/day  
• chronic daily NSAIDS  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 28 of 38 • immunosuppressants including calcineurin inhibitors, corticosteroids, or biological or cytotoxic  
immunosuppressants (e.g. imuran, methotrexate, cyclosporine, etanercept, infliximab)  
• antibiotics  within 14 days of immunizations  
• additional live vaccinations  within  60 days  of BCG immunizations  
 
7.8.2 Warnings  
BCG contains live, attenuated mycobacteria, and carries risk for adverse consequences particularly in 
immunocompromised individuals for whom the attenuated strain could become pathogenic as described below 
(section 9.1, BCG vaccine risks ). 
8 BIOSTATISTICAL ANALYSIS  
8.1 Statistical methods  
This is  a single -site, open -label pilot clinical trial in which t welve older adult volunteers  with normal cognition or 
MCI will be recruited for BCG vaccination with the intent of generating preliminary descriptive data on IIR and 
neurobiological biomarker effects a nd evaluate  tolerability, safety and study feasibility. No sample size calculations 
are performed as no prespecified comparisons are planned. Statistical analyses will describe baseline characteristics 
of the sample and change in biomarker s, safety  and cli nical measures, with pre -post paired t -tests or non -parametric 
equivalents (Wilcoxon sign -rank) used to evaluate within subject change. All outcomes in this pilot study are 
considered exploratory and no claims are attached to them, thus multiple comparison  correction is not applied. A P 
value <0.05 will be considered significant.  Findings will be used to inform the design of subsequent placebo -
controlled trials of BCG vaccination for prevention and/or disease modification of Alzheimer's disease and related 
disorders.  
9 RISKS AND DISCOMFORTS  
9.1 BCG Vaccine  Risks  
The BCG injection is associated with minimal, brief discomfort . The following risks may also be associated with 
BCG vaccination per the manufacturer product insert.  
Although BCG vaccination often causes local reactions, serious or long -term complications are rare. Reactions that 
can be expected after vaccination include moderate axillary or cervical lymphadenopathy and induration and 
subsequent pustule formation at the injection site; these reactio ns can persist for as long as 3 months after 
vaccination. The intensity and duration of the local reaction depends on the depth of penetration of the puncture 
device and individual variations in patients’ tissue reactions. Slight tenderness at the puncture  site may be 
encountered as well as some itching. The initial skin lesions usually appear within 10 –14 days and consist of small 
red papules at the site. The papules reach maximum diameter (about 3 mm) after 4 to 6 weeks, after which they 
may scale and the n slowly subside.  More serious local reactions include ulceration at the vaccination site, regional 
suppurative lymphadenitis with draining sinuses, and caseous lesions or purulent draining at the puncture site. These 
manifestations might occur up to 5 mon ths after vaccination and could persist for several weeks.  
Acute, localized irritative toxicities of BCG may be accompanied by systemic manifestations, consistent with a 
“flu-like” syndrome. Systemic adverse effects of 1 –2 days’ duration such as fever, ano rexia, myalgia, and neuralgia, 
often reflect hypersensitivity reactions. However, symptoms such as fever of 103  °F or greater, or acute localized 
inflammation persisting longer than 2 –3 days suggest active infections, and evaluation for serious infectious 
complication should be considered.  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 29 of 38 Rare adverse events (mostly suppurative adenopathy) have been reported in Europe and other locales, mostly in the 
setting of mistakenly subcutaneous, rather than intradermal vaccination. The frequency of more severe cuta neous 
reactions, such as an ulcer >1 cm, axillary adenopathy which may be suppurative, or other localized skin reactions, 
is approximately 0.02% for first vaccinations and 0.04% for second vaccinations. Suppurative adenopathy is not 
treated but observed.  
An allergic reaction can occur including serious reactions such as s hock or anaphylaxi s. Although anaphylaxis is 
very rare, the subjects will be observed for an allergic reaction after BCG vaccination.  
The most serious complication of BCG vaccination  is disseminated BCG infection. The most frequent disseminated 
infection is BCG osteomyelitis (0.01 to 43 cases per million doses of vaccine administered) which usually occurs 4 
months to 2 years after vaccination. Fatal disseminated BCG infection has occurred at  a rate of 0.06 –1.56 cases per 
million doses; these deaths occurred primarily among immunocompromised persons (tested for and excluded from 
this study) . 
9.2 Lumbar puncture  
Pain may occur during the procedure. This is usually temporary, confined to the lower back, and minimized with 
the cutaneous and soft tissue administration of 1% lidocaine as a local anesthetic. Short -lived LP associated 
headaches occur in <1% -36% of subjects with an incidence that decreases with age. Less commonly, a persistent 
low-pressure headache may develop as a result of a post -LP CSF leakage . Lower rates of post -LP headache have 
been noted with the atraumatic  needle s that will be prioritized for  use in t his study.  Potentially more serious, but 
very rare risks, include infection, damage to radicular nerves and bleeding into the lumbar CSF space. The risk of 
these procedure related complications is much less than 1%. There is also a very rare risk of an all ergic reaction to 
the lidocaine.  
 
9.3 Phlebotomy   
The risks associated with having blood drawn  include  bruising and local discomfort. Rarely an infection may occur 
at this site, and if an infection does occur it will be  assessed  and treated  by the study physician.   
9.4 Neurocognitive testing  
The neurocognitive tests that will be administered to assess mental performance may be stressful and potentially 
cause anxiety, fatigue, and frustration. In our prior experience with similar protocols, risks  have occurred 
infrequently and very few subjects have terminated testing. However, testing will be discontinued immediately 
upon any request by the subject to do so.  
 
9.5 Neuro psychiatric and Functional Questionnaires  
Questionnaires administered during the pr otocol may cause subjects to feel sad or upset about their diagnosis and 
daily functioning or how it affects their quality of life. Study staff is experienced with such evaluations and 
sensitive to these issues. Any question can be omitted per the subject’ s request.  
 
9.6 Radiation  
In general, exposure to ionizing radiation may have health risks. Subjects who require Fluoroscopy -guided lumbar 
puncture will be exposed to a  maximum of approximately 0.18 millisieverts (mSv) for this research . This is the 
same amount of radiation as a person would normally get in 21 days from natural background radiation and is 
comparable to the dose from a single chest x -ray.   
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 30 of 38 9.7 Other Risks  
Reviewing health -related information might be stressful or make the subject feel uncomfortable. Subjects do not 
have to answer any questions they  do not want to.  In addition, there may be incidental medical findings as a result 
of the clinical  examination s. No research results will be placed in their medical record. No health or medical 
information obtained from research on a subject’s sample will be returned to the them or their physician.  Coded, 
de-identified data/samples may be provided to authorized federal data repositories for broad -sharing with 
approved researchers. As with all database systems, there is a slight risk that there could b e a breach in the 
security of these data banks resulting in the access of information. Safeguards  are in place to minimize privacy 
risks.  
10 POTENTIAL BENEFITS  
The aim of this trial is to further understand  the IIR and  neurobiological biomarker effects of BCG . We do not know 
what the potential benefits may be to subjects who choose to participate in this study.  There may be no benefit at 
all. This trial is assessing multiple biomarkers in concert with clinical outcomes, which will provide a detailed 
understan ding of the effect of BCG  and provide a well -curated data set for the Alzheimer’s research community to 
improve our understanding of the disease with an eye towards better treatments and prevention.  
 
11 MONITORING AND QUALITY ASSURANCE  
11.1 Independent Monitoring  of Source Data 
The PI will ultimately be responsible for the validity and integrity of the data collected at the MGH site, and for 
ensuring that the study is conducted in accordance with the IRB -approved protocol. After data is collected and 
recorded on forms, the study coordinator may input the data into the Partners approved StudyTRAX  EDC within 
7 days of the study visit. Entries will be reviewed for accuracy and completeness by a second study coordinator. 
Finally, the PI or his designee (Co -I) will conduct monthly reviews to check that data in StudyTRAX  accurately 
reflects the data collected on th e original data capture forms. The research team (PI, Co -I, research coordinators) 
will subsequently meet to discuss the results of this review, as well as case report forms and source 
documentation.  
 
All electronic documentation will be stored on passwor d-protected devices in locked cabinets located in secured 
areas. Paper forms will be stored in locked cabinets located in secured areas.  
 
11.2 Safety Monitoring  
The adverse event (AE) definitions and reporting procedures provided in this protocol comply with a ll applicable 
United States Food and Drug Administration (FDA) regulations and International Confer ence on Harmoniz ation 
(ICH) guidelines. The PI will carefully monitor each subject throughout the study for possible adverse events. All 
AEs will be document ed on CRFs designed specifically for this purpose. It will be important to report all AEs, 
whether serious or non -serious.  
 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 31 of 38 11.3 Adverse Event Reporting Guidelines  
11.3.1   Adverse Event  
An adverse event (AE) is any unfavorable and unintended sign (including a clinical ly significant abnormal 
laboratory finding, for example), symptom, or disease temporally associated with a study, use of a drug product or 
device, whether or not considered related to the drug product or device.  
 
Examples of adverse events include: new con ditions, worsening of pre -existing conditions, clinically significant 
abnormal physical examination signs (i.e. skin rash, peripheral edema, etc.), or clinically significant abnormal test 
results (i.e. lab values or vital signs), with the exception of outc ome measure results, which are not being recorded 
as adverse events in this trial (they are being collected, but analyzed separately). The BCG vaccine causes a 
circular and contained inflammatory response with scab followed by scar formation.  For this stu dy, this expected 
BCG vaccine site reaction is not considered an adverse event . Stable chronic conditions (e.g. arthritis) that are 
present prior to the start of the study and do not worsen during the trial are NOT considered adverse events. 
Chronic condit ions that occur more frequently (for intermittent conditions) or with greater severity are considered 
as worsened and therefore would be recorded as adverse events. Adverse events are generally detected in two 
ways:  
• Clinical → symptoms reported by the subject or signs detected on examination.  
• Ancillary Tests → abnormalities of vital signs, laboratory tests, and other diagnostic procedures 
(other than the outcome measures, the results of which are not being captured as AEs).  
 
If discernible at the time of completing the AE log, a specific disease or syndrome rather than individual 
associated signs and symptoms should be identified by a clinician investigator  and recorded on the AE log. 
However, if an observed or reported sign, sy mptom, or clinically significant laboratory anomaly is not considered   
to be a component of a specific disease or syndrome, then it should be recorded as a separate AE on the AE log. 
Clinically significant laboratory abnormalities, such as those that requi re intervention, are those that are identified 
as such by a clinician investigator . 
 
Subjects will be monitored for adverse events from the time they sign consent until completion of their 
participation in the study (defined as death, consent withdrawal, l oss to follow up, early study termination for 
other reasons, or following completion of the entire study). An unexpected adverse event is any adverse event, the 
specificity or severity of which is not consistent with the current  product insert . 
 
The study procedures and the well -being of all participants will be monitored closely by the Principal 
Investigator, Steven Arnold MD, and the  clinician  Co-Investigators . Throughout the course of the study, constant 
feedback with the subject is maintained in order t o assess comfort and safety and to minimize risks throughout the 
procedure. The above investigators will be responsible for determining if a subject should be removed from the 
study. Criteria for removal include the following: 1) if a subject is unwilling or unable to participate in study 
procedures 2) if the subject refuses to participate and consent, 3) if the subject acquires a medical condition that 
prohibits further participation, 4) if in the opinion of the MGH principal investigator, Dr. Steven Arnol d, it is 
decided that it is not in the subject’s best interest to continue participation.  
 
Unanticipated problems including adverse events will be reported to the PHRC as described in the PHRC policy 
on Unanticipated Problems Involving Risks to Subjects or Others including adverse events.  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 32 of 38  
All data will be managed in compliance with applicable regulatory requirements. The study coordinator, under the 
supervision of the PI, will collect, transcribe, correct, and transmit the data onto source docum ents, Case Report 
Forms (CRFs), and/or other forms used to report, track, and record clinical research data.  
 
11.3.1.1  Serious Adverse Events  
All adverse events will be reviewed by the Principal Investigator, Dr. Steven Arnold, and will be reported to 
Partners IRB and to the Human Research Committee (HRC) in accordance with HRC Guidelines. A serious 
adverse event (SAE) is defined as an adverse e vent that meets any of the following criteria:  
1. Results in death.  
2. Is life threatening: that is, poses an immediate risk of death as the event occurs.  
o This serious criterion applies if the study subject, in the view of the PI, is at immediate risk of 
death f rom the AE as it occurs. It does not apply if an AE hypothetically might have caused death 
if it were more severe.  
3. Requires inpatient hospitalization or prolongation of existing hospitalization.  
o Hospitalization for an elective procedure or a routinely sche duled treatment is not an SAE by this 
criterion because an elective or scheduled “procedure” or a “treatment” is not an untoward 
medical occurrence.  
4. Results in persistent or significant disability or incapacity.  
o This serious criterion applies if the “disab ility” caused by the reported AE results in a substantial 
disruption of the subject’s ability to carry out normal life functions.  
5. Results in congenital anomaly or birth defect in the offspring of the subject.  
6. Necessitates medical or surgical intervention t o preclude permanent impairment of a body function or 
permanent damage to a body structure.  
7. Important medical events that may not result in death, are not life -threatening, or do not require 
hospitalization may also be considered SAEs when, based upon appr opriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include blood dyscrasias or 
convulsions that do not result in inpatient hospitalization.  Shock or anaphylaxis as a result of BCG 
vaccination will also be documented as SAEs.  
 
An inpatient hospital admission in the absence of a precipitating, treatment -emergent, clinical adverse event may 
meet criteria for "seriousness" but is not an adverse experience and  will therefore not be considered an SAE. An 
example of this would include  a social admission (subject admitted for reasons other than medical, e.g., lives far 
from the hospital, has no place to sleep).  
 
Any adverse reaction that is serious, unexpected, and associated with the use of the product  will be reported to the 
FDA  in an IND safety report no more than 15 calendar days  after the PI determines that the suspected adverse 
reaction qualifies for reporting, or 7 days for unexpected fatal or life -threatening adverse reaction reports.   
 
The PI is responsible for classifying  adverse events as serious or non -serious  and determining if there is 
reasonable possibility that the drug was the cause.  If the PI is not available to assess seriousness and relatedness 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 33 of 38 within 24 hours, a clinician investigator will make the assessment an d speak with the PI as soon as they are 
available.  
 
11.3.2  Assessment and Recording of Adverse Events  
The PI will carefully monitor each subject throughout the study for possible AEs. All AEs will be documented on 
CRFs designed specifically for this purpose. All AEs will be collected and reported in the EDC system.  
 
11.3.3  Assessment of Adverse Events  
At each visit (including telephone visits), the subject will be asked if they had any problems or symptoms since 
their last visit in order to determine the occurrence of ad verse events. If the subject reports an adverse event, the 
Investigator will probe further to determine:  
• Type of event  
• Date of onset and resolution (duration)  
• Severity (mild, moderate, severe)  
• Seriousness (does the event meet the above definition for an SA E) 
• Causality, relation to investigational protocol  
• Outcome  
 
11.3.4  Relatedness of Adverse Event to Investigational Protocol  
 
1. Not Related:  Concomitant illness, accident, or event with no reasonable association with 
protocol.  
2. Unlikely:  The reaction has little or no temporal sequence from administration of the 
investigational protocol, and/or a more likely alternative etiology exists.  
3. Possibly Related:  The reaction follows a reasonably temporal sequence from administration of the 
investigational proto col and follows a known response pattern to the suspected 
investigational protocol; the reaction could have been produced by the 
investigational protocol or could have been produced by the subject’s clinical state 
or by other modes of therapy administered to the subject.  
4. Probably Related:  The reaction follows a reasonably temporal sequence from administration of 
investigational protocol; is confirmed by discontinuation of the investigational 
protocol or by re -challenge; and cannot be reasonably explaine d by the known 
characteristics of the subject’s clinical state.  
5. Definitely Related:  The reaction follows a reasonable temporal sequence from administration of 
investigational protocol; that follows a known or expected response pattern to the 
investigat ional protocol; and that is confirmed by improvement on stopping of the 
investigational protocol, and reappearance of the reaction on repeated exposure.  
 
11.3.5  Recording of Adverse Events  
All clinical adverse events are recorded in the Adverse Event (AE) Log in  the subject’s study binder. Study staff 
should fill out the AE Log and enter the AE information into the EDC system within 48 hours of learning of a 
new AE or receiving an update on an existing AE.  
 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 34 of 38 Entries on the AE Log (and into the EDC) will include th e following: name and severity of the event, the date of 
onset, the date of resolution, relationship to investigational product, action taken, and primary outcome of event.  
 
11.3.6  Adverse Events and Serious Adverse Events - Reportable Events  
The following are considered reportable events and must be reported via the EDC system within 24 hours of study 
staff being notified of the event.  
• All events that meet the above criteria for Serious Adverse Events  
 
12 DATA COLLECTION AND MANAGEMENT  
12.1 Purpose of EDC  
Study data will be collected and managed using Studytrax electronic data capture software.  The purpose of 
Studytrax is to track subject enrollment and flow through the study (e.g. Scheduling of visits), capture data 
measures, and facilitate the transf er of data into statistical packages for analysis. In compliance with HIPPA 
regulations, the database security features of Studytrax target multiple levels including the data element (e.g., 
restricted access to fields), user (e.g., password authentication access), application (e.g., role -based access to 
features, access audit trails), and hosting services (e.g., firewall, secure sockets layer). These features ensure access 
control, audit control, data integrity, user authentication, and transmission securit y. The research project will be set 
up in Studytrax to ensure exported datasets are de -identified as defined in the HIPAA privacy regulation [45 C.F.R. 
§164.514 (b)(2)]. A 21 CFR Part 11 compliance document is available upon request from the creators of th e 
software, a company called ScienceTRAX, LLC.  
12.2 Role of Data Management  
All data will be managed in compliance with applicable regulatory requirements. Study personnel will collect, 
transcribe, correct, and transmit the data onto source documents, Case Repo rt Forms (CRFs), and/or other forms 
used to report, track, and record clinical research data. Data management is responsible for developing, testing, and 
managing clinical data management activities.  
 
12.3 Data Entry and Checks  
The study personnel are instructe d to enter information into Study trax within 7 days. Data capture is the 
responsibility of the staff under the supervision of the PI. During the study, the PI must maintain complete and 
accurate documentation for the study.  
 
The Studytrax platform provides  password protection. An edit checking and data clarification process will be put 
in place to ensure accuracy of the data. Logic and range checks as well as more sophisticated rules will be built 
into the system to provide immediate error checking of the d ata entered. The system has the capability to 
automatically create electronic queries for forms that contain data that are out of range, out of window, missing, 
or not calculated correctly.  
 
12.4 Data Lock Process  
The platform will have the ability to lock the project -specific visits to prevent any modification of data once the 
project is closed. Once this option is activated, every user will have Read -Only access to the data.  
 
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 35 of 38 12.5 Data Handling and Record Keeping  
The PI is responsible for ensuring accuracy, completeness, legibility, and timeliness of the data reported. Data 
reported in the eCRF derived from source documents should be consistent with the source documents and 
discrepancies should be explained.  
 
12.6 Confidentiality  
Studytrax hosted solutio ns are fully HIPAA Compliant and ensure access control, audit control, data integrity, user 
authentication, and transmission security. Studytrax uses the data center services of Rackspace, a premier hosting 
company. Rackspace offers top of the line hosting  facilities. As a summary of the Rackspace facilities: (1) Access 
to data center is secured by Biometric hand scanners and monitored 24×7 by closed circuit cameras. (2) Public 
access to data center is strictly forbidden. Only level three technicians are pe rmitted in the data center. (3) HVAC 
[Heating Ventilation Air Conditioning] systems are used to completely circulate and filter all the air every 90 
seconds. (4) Continuous UPS [Uninterrupted Power Supply] systems keep all servers up and running in the eve nt 
of a total power outage. (5) Diesel engines are located on -site to provide power for extended power outages. (6) 
Enterprise -class routing equipment used in conjunction with multiple fiber carriers to ensure zero downtime due to 
network access.  
Data is p rotected from loss by the following: (1) A redundant array of independent disk [RAID] Level 5 is used to 
ensure that data will not be lost if a hard drive fails, (2) full database backups are done nightly, (3) database log file 
backups are done every 15 mi nutes, (3) database integrity checks and index maintenance are performed nightly, (4) 
the database and log backup files are retained as part of Rackspace’s backup process and also transferred every hour 
to Microsoft’s Azure geographically redundant storage . 
Data security is assured by the following: (1) All server requests are transmitted over SSL using 256 -bit encryption, 
(2) a dedicated Cisco router firewall only allows requests to Studytrax, (3) the database is stored on a separate server 
in a private in dependent subnet with no public IP address, (4) database and log files are encrypted, and (5) database 
and log backups are encrypted.  
12.7 Retention of Records  
Research records will be retained in accordance with IRB policies.  
 
12.8 Publications  
The Principal Inves tigator, Steven E. Arnold, will be responsible for publication of results from this study. Dr. 
Arnold’s responsibilities will include the following:  
• Analyze and interpret data gathered in this study and write publications from these data  
• Submit manuscripts to selected journals and address peer reviewers’ comments  
• Submit abstracts to selected meetings and present data at the meetings  
• Determine authorship on the basis of the Uniform Requirements for Manuscripts  
   
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 36 of 38 13 REFERENCES  
 
1 Association, A. s. 2019 Alzheimer’s disease facts and figures. Alzheimer’s Dementia , 321 -387 (2019).  
2 Kumar, D. K.  et al.  Amyloid -beta peptide protects against microbial infection in mouse and worm models 
of Alzheimer's disease. Sci Tr ansl Med  8, 340ra372, doi:10.1126/scitranslmed.aaf1059 (2016).  
3 Heneka, M. T.  et al.  Neuroinflammation in Alzheimer's disease. Lancet Neurol  14, 388 -405, 
doi:10.1016/S1474 -4422(15)70016 -5 (2015).  
4 Gelders, G., Baekelandt, V. & Van der Perren, A. Linking Neuroinflammation and Neurodegeneration in 
Parkinson's Disease. J Immunol Res  2018 , 4784268, doi:10.1155/2018/4784268 (2018).  
5 Schwab, A. D.  et al.  Immunotherapy for Parkinson's disease. Neurobiol Dis  137, 104760, 
doi:10.1016/j.nbd.2020.104760 (2020).  
6 Bellucci, A., Bugiani, O., Ghetti, B. & Spillantini, M. G. Presence of reactive microglia and 
neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener 
Dis 8, 221 -229, doi:10.1159/000322228 (2011).  
7 Laurent, C., Bue e, L. & Blum, D. Tau and neuroinflammation: What impact for Alzheimer's Disease and 
Tauopathies? Biomed J  41, 21-33, doi:10.1016/j.bj.2018.01.003 (2018).  
8 Bright, F.  et al.  Neuroinflammation in frontotemporal dementia. Nat Rev Neurol  15, 540 -555, 
doi:10.1038/s41582 -019-0231 -z (2019).  
9 McCauley, M. E. & Baloh, R. H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol  137, 715 -
730, doi:10.1007/s00401 -018-1933 -9 (2019).  
10 Monsonego, A.  et al.  Increased T cell reactivity to amyloid β protein in older humans. Journal of Clinical 
Investigation  112, 415 -422, doi:10.1172/JCI200318104.Introduction (2003).  
11 Shen, X. N.  et al.  Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta -
analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry  90, 590 -598, 
doi:10.1136/jnnp -2018 -319148 (2019).  
12 Pfeffer, R. I., Kurosaki, T. T., Harrah C. H., J., Chance, J. M. & Filos, S. Measurement of funct ional 
activities in older adults in the community. J Gerontol  37, 323 -329, doi:10.1093/geronj/37.3.323 (1982).  
13 La Rosa, F.  et al.  Immune and Imaging Correlates of Mild Cognitive Impairment Conversion to 
Alzheimer's Disease. Scientific Reports  7, 1-10, d oi:10.1038/s41598 -017-16754 -y (2017).  
14 Saresella, M.  et al.  The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol 
Neurodegener  11, 23, doi:10.1186/s13024 -016-0088 -1 (2016).  
15 Gate, D.  et al.  Clonally expanded CD8 T cells patrol the  cerebrospinal fluid in Alzheimer's disease. 
Nature  577, 399 -404, doi:10.1038/s41586 -019-1895 -7 (2020).  
16 Larbi, A.  et al.  Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild alzheimer's disease. 
Journal of Alzheimer's Disease  17, 91-103, doi:10.3233/JAD -2009 -1015 (2009).  
17 Baek, H.  et al.  Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg -AD 
Alzheimer's disease model. Oncotarget  7, 69347 -69357, doi:10.18632/oncotarget.12469 (2016).  
18 Baruch, K.  et al.  Breaking immu ne tolerance by targeting Foxp3(+) regulatory T cells mitigates 
Alzheimer's disease pathology. Nat Commun  6, 7967, doi:10.1038/ncomms8967 (2015).  
19 Dansokho, C.  et al.  Regulatory T cells delay disease progression in Alzheimer -like pathology. Brain  139, 
1237-1251, doi:10.1093/brain/awv408 (2016).  
20 Ciccocioppo, F.  et al.  The Characterization of Regulatory T -Cell Profiles in Alzheimer's Disease and 
Multiple Sclerosis. Sci Rep  9, 8788, doi:10.1038/s41598 -019-45433 -3 (2019).  
21 Gelders, G., Baekelandt, V. & d er Perren, A. Linking Neuroinflammation and Neurodegeneration in 
Parkinson's Disease. J Immunol Res  2018 , 4784268, doi:10.1155/2018/4784268 (2018).  
22 Bellucci, A., Bugiani, O., Ghetti, B. & Spillantini, M. G. Presence of reactive microglia and 
neuroinflam matory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener 
Dis 8, 221 -229, doi:10.1159/000322228 (2011).  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 37 of 38 23 Laurent, C., Buee, L. & Blum, D. Tau and neuroinflammation: What impact for Alzheimer's Disease and 
Tauopathies? Biomed  J 41, 21-33, doi:10.1016/j.bj.2018.01.003 (2018).  
24 Bright, F.  et al.  Neuroinflammation in frontotemporal dementia. Nat Rev Neurol  15, 540 -555, 
doi:10.1038/s41582 -019-0231 -z (2019).  
25 McCauley, M. E. & Baloh, R. H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol  137, 715 -
730, doi:10.1007/s00401 -018-1933 -9 (2019).  
26 Walk, J.  et al.  Outcomes of controlled human malaria infection after BCG vaccination. Nat Commun  10, 
874, doi:10.10 38/s41467 -019-08659 -3 (2019).  
27 van 't Wout, J. W., Poell, R. & van Furth, R. The role of BCG/PPD -activated macrophages in resistance 
against systemic candidiasis in mice. Scand J Immunol  36, 713 -719, doi:10.1111/j.1365 -
3083.1992.tb03132.x (1992).  
28 Lawton, G. Trials of BCG vaccine will  test for covid -19 protection. New Sci  246, 9, doi:10.1016/S0262 -
4079(20)30836 -8 (2020).  
29 Guallar -Garrido, S. & Julian, E. Bacillus Calmette -Guerin (BCG) Therapy for Bladder Cancer: An 
Update. Immunotargets Ther  9, 1-11, doi:10.2147/ITT.S202006 (2020).  
30 Stewart, J. H. t. & Levine, E. A. Role of bacillus Calmette -Guerin in the treatment of advanced 
melanoma. Expert Rev Anticancer Ther  11, 1671 -1676, doi:10.1586/era.11.163 (2011).  
31 Powles, R. L.  et al.  Maintenance of remission in acute myelogenous leuka emia by a mixture of B.C.G. 
and irradiated leukaemia cells. Lancet  2, 1107 -1110, doi:10.1016/s0140 -6736(77)90549 -9 (1977).  
32 Villumsen, M.  et al.  Risk of lymphoma and leukaemia after bacille Calmette -Guerin and smallpox 
vaccination: a Danish case -cohort s tudy. Vaccine  27, 6950 -6958, doi:10.1016/j.vaccine.2009.08.103 
(2009).  
33 Paolillo, A.  et al.  The effect of Bacille Calmette -Guerin on the evolution of new enhancing lesions to 
hypointense T1 lesions in relapsing remitting MS. J Neurol  250, 247 -248, doi:10 .1007/s00415 -003-0967 -
6 (2003).  
34 Ristori, G.  et al.  Use of Bacille Calmette -Guerin (BCG) in multiple sclerosis. Neurology  53, 1588 -1589, 
doi:10.1212/wnl.53.7.1588 (1999).  
35 Ristori, G.  et al.  Effects of Bacille Calmette -Guerin after the first demyelinat ing event in the CNS. 
Neurology  82, 41-48, doi:10.1212/01.wnl.0000438216.93319.ab (2014).  
36 Faustman, D. L.  et al.  Proof -of-concept, randomized, controlled clinical trial of Bacillus -Calmette -Guerin 
for treatment of long -term type 1 diabetes. PLoS One  7, e41756, doi:10.1371/journal.pone.0041756 
(2012).  
37 Kuhtreiber, W. M.  et al.  Long -term reduction in hyperglycemia in advanced type 1 diabetes: the value of 
induced aerobic glycolysis with BCG vaccinations. NPJ Vaccines  3, 23, doi:10.1038/s41541 -018-0062 -8 
(2018).  
38 Freyne, B. & Curtis, N. Does neonatal BCG vaccination prevent allergic disease in later life? Arch Dis 
Child  99, 182 -184, doi:10.1136/archdischild -2013 -305655 (2014).  
39 Kiraly, N., Allen, K. J. & Curtis, N. BCG for the prevention of food allerg y - exploring a new use for an 
old vaccine. Med J Aust  202, 565 -566, doi:10.5694/mja14.01511 (2015).  
40 Steenhuis, T. J.  et al.  Bacille -Calmette -Guerin vaccination and the development of allergic disease in 
children: a randomized, prospective, single -blind  study. Clin Exp Allergy  38, 79-85, doi:10.1111/j.1365 -
2222.2007.02859.x (2008).  
41 Thostesen, L. M.  et al.  Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A 
randomized clinical trial. Allergy  73, 498 -504, doi:10.1111/all.13314 (201 8). 
42 Lacan, G.  et al.  Bacillus Calmette -Guerin vaccine -mediated neuroprotection is associated with regulatory 
T-cell induction in the 1 -methyl -4-phenyl -1,2,3,6 -tetrahydropyridine mouse model of Parkinson's disease. 
J Neurosci Res  91, 1292 -1302, doi:10.1002/jnr.23253 (2013).  
43 Yong, J.  et al.  BCG vaccine -induced neuroprotection in a mouse model of Parkinson's disease. PLoS One  
6, e16610, doi:10.1371/journal.pone.0016610 (2011).  
 
 
Effects of BCG Immunization on Cerebrospinal Fluid and Blood -Based Biomarkers in Older Adults: A Pilot  
Versi on 7.0 
Version Date: 28FEB2022  
Page 38 of 38 44 Faustman, D. L. Benefits of BCG -Induced Metabolic Switch from Oxid ative Phosphorylation to Aerobic 
Glycolysis in Autoimmune and Nervous System Diseases. J Intern Med , doi:10.1111/joim.13050 (2020).  
45 Gofrit, O. N.  et al.  Bacillus Calmette -Guerin (BCG) therapy lowers the incidence of Alzheimer's disease 
in bladder cancer  patients. PLoS One  14, e0224433, doi:10.1371/journal.pone.0224433 (2019).  
46 Baek, H.  et al.  Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg -AD 
Alzheimer's disease model. Oncotarget  7, 69347 -69357, doi:10.18632/oncotarget.12469 (20 16). 
47 Dansokho, C.  et al.  Regulatory T cells delay disease progression in Alzheimer -like pathology. Brain  139, 
1237 -1251, doi:10.1093/brain/awv408 (2016).  
48 Ciccocioppo, F.  et al.  The Characterization of Regulatory T -Cell Profiles in Alzheimer's Disease  and 
Multiple Sclerosis. Sci Rep  9, 8788, doi:10.1038/s41598 -019-45433 -3 (2019).  
49 Trombetta, B. A.  et al.  The technical reliability and biotemporal stability of cerebrospinal fluid 
biomarkers for profiling multiple pathophysiologies in Alzheimer's diseas e. PLoS One  13, e0193707, 
doi:10.1371/journal.pone.0193707 (2018).  
50 Burger, D. E.  et al.  Novel automated blood separations validate whole cell biomarkers. PLoS One  6, 
e22430, doi:10.1371/journal.pone.0022430 (2011).  
51 Kühtreiber, W. M.  et al.  Long -Term reduction in hyperglycemia in advanced type 1 diabetes: The value 
of induced aerobic glycolysis with BCG vaccinations. npj Vaccines  3, doi:10.1038/s41541 -018-0062 -8 
(2018).  
52 Okubo, Y., Mera, T., Wang, L. & Faustman, D. L. Homogeneous expansion of human T -regulatory cells 
via tumor necrosis factor receptor 2. Sci Rep  3, 3153, doi:10.1038/srep03153 (2013).  
53 Teng, E.  et al.  Utility of the functional activities questionnaire for distinguishing mild cognitive 
impairment from very mild Alzheimer disease. Alzheimer Dis Assoc Disord  24, 348 -353, 
doi:10.1097/WAD.0b013e3181e2fc84 (2010).  
54 Nasreddine, Z. S.  et al.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild 
cognitive impairment. J Am Geriatr Soc  53, 695 -699, doi:10.1111/j.1532 -5415.20 05.53221.x (2005).  
55 Randolph, C., Tierney, M. C., Mohr, E. & Chase, T. N. The Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol  20, 310 -
319, doi:10.1076/jcen.20.3.310.823 (1998).  
56 O'Bryant, S. E. et al.  Validation of the new interpretive guidelines for the clinical dementia rating scale 
sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol  67, 746 -749, 
doi:10.1001/archneurol.2010.115 (2010).  
57 Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Jr., Chance, J. M. & Filos, S. Measurement of functional 
activities in older adults in the community. J Gerontol  37, 323 -329, doi:10.1093/geronj/37.3.323 (1982).  
 